According to the latest market research study published by P&S Intelligence, the global influenza diagnostics market was valued at USD 946.9 million in 2023 and is anticipated to grow at a CAGR of 7.9%, reaching USD 1,603.1 million by 2030. The primary drivers of this growth include increasing rates of chronic diseases exacerbated by influenza, the aging population, and enhanced government efforts to track and manage flu outbreaks. The continuous advancement of diagnostic technologies and the development of more effective tools to detect and manage influenza have significantly contributed to market expansion. Governments are funding research for better diagnostic solutions, such as the NIH’s support for flu-related initiatives, which has further boosted market dynamics.
Technological innovations, particularly in molecular
diagnostics and point-of-care testing, are shaping the future of the influenza
diagnostics market. The rising development of combination tests for influenza
and COVID-19 is also expected to drive market growth. With an increasing number
of diagnostic tests becoming available for smaller clinics and research
institutions, these innovations are making influenza diagnostics more
accessible and efficient.
Key Insights
Product Segmentation
The test kits and reagents segment led the market in 2023,
capturing 60% of the total market share. This dominance is driven by the
widespread availability of test kits and their affordability, which make them
popular among healthcare providers and consumers alike. Point-of-care testing
kits are becoming especially significant as they allow for quick, at-home
diagnosis, eliminating the need for in-person visits.
Instruments Segment
The instruments segment is expected to grow at the highest
CAGR of 8.3% from 2024 to 2030, fueled by increased healthcare spending
globally. This growth reflects the rising number of hospitals and diagnostic
centers, which are investing in advanced diagnostic instruments for more
reliable influenza detection.
Test Types
Traditional diagnostic tests hold a significant market
share, with rapid influenza diagnostic tests (RIDTs) playing a pivotal role due
to their ease of use and rapid results. However, molecular diagnostic tests,
such as RT-PCR, are also experiencing high demand due to their greater accuracy
in detecting influenza, particularly influenza B, and for determining the
severity of infections.
Geographical Insights
North America accounted for the largest share, 65%, of the
global market in 2023. The region’s strong healthcare infrastructure, high
prevalence of influenza, and extensive government health programs are driving
market expansion. This region is also leading in the adoption of advanced
diagnostic tools and technologies.
Technological Advancements
Rapid advancements in diagnostic technologies, such as the
development of combination tests for influenza and COVID-19, are transforming
the market. These innovations not only improve diagnostic speed but also allow
for simultaneous screening of multiple infections, enhancing the efficiency of
flu monitoring and management in clinical settings.
Competitive Landscape
Major companies in the influenza diagnostics market are
focusing on the development of advanced and more reliable diagnostic tools. For
example, Roche has launched a combination test for COVID-19 and influenza,
addressing the increased demand for multi-disease diagnostic solutions.
Moreover, the rising trend of point-of-care (POC) testing, including at-home
test kits, is expected to increase competition in the market.
Opportunities
No comments:
Post a Comment